Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sponsor: Sling Therapeutics, Inc.
Listed as NCT06112340, this PHASE2/PHASE3 trial focuses on Endocrine System Diseases and Exophthalmos and remains actively recruiting participants. Sponsored by Sling Therapeutics, Inc., it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sling Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .